Breast Cancer Clinical Trial
Official title:
Qualitative and Quantitative Analysis of Cystic Breast Masses by Contrast Enhanced Ultrasound: Is Biopsy Necessary?
The overarching goal of the proposed research is to evaluate whether qualitative and quantitative parameters in real time contrast enhanced ultrasound (CEUS) can aid in assessing suspicious indeterminate cystic appearing breast masses and ultimately determine whether or not an ultrasound guided biopsy is necessary. The underlying hypothesis is that breast masses (given BIRADS 4) that lack enhancement on CEUS will have a benign histology obtained by ultrasound guided core biopsy and/or surgery. Then, in the future, these non-enhancing cystic lesions can be followed and do not need biopsy intervention.
Breast cancer is the most frequently diagnosed cancer in women. To diagnose these cancers,
more than 1.6 million breast biopsies are performed each year in the United States, of which
more than 60% have benign pathology. A large percentage of the benign biopsies show
fibrocystic changes of the breast on histology. These biopsies can be avoided with better
diagnostic tools identifying fibrocystic change. The Investigators propose that contrast
enhanced ultrasound (CEUS) can aid in classifying and predicting if a cystic appearing breast
mass is benign or malignant, and can be a supplemental imaging tool to mammography and
conventional gray-scale ultrasound (US).
In standard clinical practice, if a breast mass appears to be cystic on gray-scale US but has
some suspicious features which make it difficult to tell if the mass is truly cystic or
solid, the decision making for follow-up versus biopsy is difficult. This leads to
unnecessary biopsies (false positives) since many of these masses are a sequel of benign
fibrosis and fibrocystic changes of the breast. CEUS may help classify these masses as cystic
or solid. The central premise is based on the microbubble contrast agent used in CEUS, since
it stays within the blood pool and will only show enhancement if a mass has solid components
and has vascular flow.
The Investigators hypothesize that indeterminate cystic breast masses will not enhance on
CEUS and will correlate with benign pathology. Quantitative CEUS parameters will also help
classify these lesions. If this is the case, then in the future, the non-enhancing cystic
breast masses will not need to be biopsied. This will decrease patient anxiety, unnecessary
interventions, and save resources.
The investigators will investigate qualitative and quantitative parameters on CEUS in
evaluating indeterminate cystic breast masses given BIRADS 4 and correlate these with
histopathology obtained by biopsy and/or surgery. This data will help them to develop
protocols to better distinguish between benign and malignant cystic appearing breast masses.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
Recruiting |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
Recruiting |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A |